Remus Pharmaceuticals Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sgo7q1ljueb3iq86t23kab2j.pdf

Key Takeaways


The Consolidation Effect: Revenue vs. Margins


B2C Branding: The Margin Expansion Engine

Swapnil Shah: "So as you know, branded generics, the price erosion doesn't happen the way it happens on a typical generic that exists in this market. So of course, there is going to be little bit on price pressure, but we feel we are going to be able to maintain healthy profit margins on these products."

Weight-Loss Portfolio: The Next Catalyst


Geographic Expansion: Latin America and Beyond

Arpit Shah: "What sets us apart is our ability to enter markets with new products in a record time so as to take the first mover advantage in short span of time."

Business Model & Competitive Positioning


Guidance & Commitments

CommitmentSpecificsTimeline
B2C share expansionB2C to reach at least 25–30% of business (from 10–15% currently)By end of this year (FY26)
B2C product countAround 250 B2C products in portfolio (from 570 currently)Within a year
Gross margin improvementStrong improvement anticipated as B2C share growsH1, H2 and coming years
Semaglutide/Mounjaro revenueFirst sales from non-patent marketsH2 FY26
Growth characterSustainable growth on current revenue base; no exorbitant growth like the consolidation-driven spikeOngoing

Key Metrics

MetricQ4 FY25
H2 FY25 consolidated revenue₹347.75 cr, +88% YoY; periods not comparable due to partial consolidation of US subsidiary in prior period
H2 FY25 consolidated EBITDA₹27.15 cr, +29% YoY
H2 FY25 consolidated net profit before minority interest₹20.57 cr, +10% YoY
H2 FY25 consolidated net profit after minority interest (Remus share)₹16.01 cr
FY25 consolidated revenue₹620.36 cr, +191% YoY; full period for US subsidiary vs partial consolidation in prior period
FY25 consolidated EBITDA₹50.67 cr, +59% YoY
FY25 consolidated net profit before minority interest₹38.42 cr, +58% YoY
FY25 consolidated net profit allocated to Remus₹29.07 cr
H2 FY25 standalone revenue₹41.49 cr, +14% YoY
H2 FY25 standalone EBITDA₹15.70 cr, +15% YoY
H2 FY25 standalone net profit₹10.71 cr, +22% YoY
FY25 standalone revenue₹79.16 cr, +23% YoY
FY25 standalone EBITDA₹28.88 cr, +26% YoY
FY25 standalone net profit₹19.90 cr, +18% YoY
R&D spend2% to 3% of turnover, expected to remain at this level
B2C share of business10% to 15% currently; expected to reach at least 25% to 30% by end of year
B2C gross margin65% to 70% (per an analyst's math)
Overall gross margin guidance40% (per an analyst's math)
B2C products currently570
B2C product target within a year~250 additional products
New trademarks and product registrations filed in H2 FY25170 filed, 35 secured and approved
Products commercialized in H2 FY25Over 10 off-patent pharmaceutical products
Products launched by Bolivia subsidiary (Relius)More than 15 across private market, pharmacy chains, hospitals, and government institutions
Brand awareness conference attendanceMore than 55 doctors and pharmacy representatives
Countries of export presenceMore than 40 countries
Share of exports from advanced and niche formulationsMore than 95%